Early results of mechanochemical ablation for small saphenous vein incompetency using 2% polidocanol. 2021

Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
Vascular Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

The aim of the present study was to investigate the early results of mechanochemical ablation (MOCA) for the treatment of small saphenous vein (SSV) incompetence. We performed a single-center, retrospective analysis of a prospectively collected database of 60 patients treated with MOCA for single-axis SSV incompetence. All procedures were performed with the patient under local anesthesia using the ClariVein catheter (Merit Medical, South Jordan, Utah) combined with 2% polidocanol and, where appropriate, additional microphlebectomy. The primary study endpoint was to assess the SSV occlusion rate at the 1-, 6-, and 12-month follow-up examinations. The secondary endpoints included the Venous Clinical Severity Score, quality of life (QoL) assessment, periprocedural pain, and further complications after the intervention and during the follow-up period. Patient QoL was assessed using the Aberdeen Varicose Vein Questionnaire. Pain was measured using a 100-mm visual analog scale. Technical success was achieved in 100% of the cases. The mean visual analog scale score on the first postoperative day was 15 mm. No major events were recorded. No neurological complications or deep vein thrombosis were observed. Minor complications included ecchymosis in 3.3% of cases (2 of 60), transient phlebitis of the SSV in 5% of cases (3 of 60), and itching in 3.3% of cases (2 of 60). At the 1-, 6-, and 12-month follow-up examinations, the occlusion rate was 100% (60 of 60), 98.3% (57 of 58), and 92.6% (50 of 54). The median Venous Clinical Severity Score had significantly decreased from 5 (interquartile range [IQR], 3-6) at baseline to 2 (IQR, 1-4) at the 1-month follow-up (P < .001), 1 (IQR, 1-2) at the 6-month follow-up (P < .001) and 1 (IQR, 0-1) at the 12-month follow-up (P < .001). The mean Aberdeen Varicose Vein Questionnaire score had improved from the baseline score of 25 ± 14.61 to 15.81 ± 13.76 at the 1-month follow-up (P < .001), to 9.81 ± 7.42 at the 6-month follow-up (P < .001) and 4.73 ± 3.32 at the 12-month follow-up (P < .001). The results of our study have shown that MOCA is a feasible, safe, and painless procedure for the treatment of SSV incompetence with an occlusion rate of 92.6% at the 12-month examination. No sural nerve injuries or other major complications were observed. The procedure also provided good clinical results and positive effects on patient QoL.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D002406 Catheterization, Peripheral Insertion of a catheter into a peripheral artery, vein, or airway for diagnostic or therapeutic purposes. Arterial Catheterization, Peripheral,Catheterization, Bronchial,Catheterization, Peripheral Arterial,Catheterization, Peripheral Venous,Peripheral Catheterization,Venous Catheterization, Peripheral,Bronchial Catheterization,PICC Line Catheterization,PICC Line Placement,PICC Placement,Peripheral Arterial Catheterization,Peripheral Venous Catheterization,Peripherally Inserted Central Catheter Line Insertion,Arterial Catheterizations, Peripheral,Bronchial Catheterizations,Catheterization, PICC Line,Catheterizations, Bronchial,Catheterizations, PICC Line,Catheterizations, Peripheral,Catheterizations, Peripheral Arterial,Catheterizations, Peripheral Venous,PICC Line Catheterizations,PICC Line Placements,PICC Placements,Peripheral Arterial Catheterizations,Peripheral Catheterizations,Peripheral Venous Catheterizations,Placement, PICC,Placement, PICC Line,Placements, PICC,Placements, PICC Line,Venous Catheterizations, Peripheral
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077423 Polidocanol An alkyl polyglycol ether of LAURYL ALCOHOL, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. It is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of ESOPHAGEAL AND GASTRIC VARICES and VARICOSE VEINS. Aethoxysclerol,Aethoxysklerol,Aetoxisclerol,Atossisclerol,Atoxysclerol,Brij 30,Brij-30,Dodecyl Ethyleneglycol Monoether,Ethoxysclerol,Hydroxypolyethoxydodecane,Laureth,Laureth 9,Laureth-1,Laureth-4,Laureth-7,Laureth-9,Lauromacrogol,Lauromacrogol 400,Lauromacrogols,Lubrol 12A9,Lubrol-PX,Nonaethylene Glycol Monododecyl Ether,Nonaethyleneglycol Monododecyl Ether,Polyethylene Glycol Monododecyl Ether,Polyethylene Glycol-7-lauryl Ether,Polyoxyethylene 9-lauryl Ether,Polyoxyethylene Lauryl Ether,Polyoxyethylene(4) Lauryl Ether,Polyoxyethylene-4-dodecyl Ether,Polyoxyethylenedodecyl Ether,Tetraethylene Glycol Dodecyl Ether,Tetraethyleneglycol Lauryl Ether,Thesit,alpha-Dodecyl-omega-hydroxypoly(oxy-1,2ethanediyl),Brij30,Dodecyl Ethyleneglycol Monoethers,Ether, Nonaethyleneglycol Monododecyl,Ether, Polyethylene Glycol-7-lauryl,Ether, Polyoxyethylene 9-lauryl,Ether, Polyoxyethylene Lauryl,Ether, Polyoxyethylene-4-dodecyl,Ether, Tetraethyleneglycol Lauryl,Ethyleneglycol Monoether, Dodecyl,Laureth 1,Laureth 4,Laureth 7,Laureths,Lauryl Ether, Tetraethyleneglycol,Lubrol PX,Monododecyl Ether, Nonaethyleneglycol,Monoether, Dodecyl Ethyleneglycol,Nonaethyleneglycol Monododecyl Ethers,Polidocanols,Polyethylene Glycol 7 lauryl Ether,Polyethylene Glycol-7-lauryl Ethers,Polyoxyethylene 4 dodecyl Ether,Polyoxyethylene 9 lauryl Ether,Polyoxyethylene 9-lauryl Ethers,Polyoxyethylene Lauryl Ethers,Polyoxyethylenedodecyl Ethers,Tetraethyleneglycol Lauryl Ethers
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
January 2020, Translational medicine @ UniSa,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
July 2022, Journal of vascular surgery. Venous and lymphatic disorders,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
December 1960, Medical services journal, Canada,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
April 2016, Phlebology,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
August 2021, Annals of vascular surgery,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
March 2013, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
March 2023, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
October 2014, Vascular,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
July 2014, Journal of vascular surgery. Venous and lymphatic disorders,
Domenico Baccellieri, and Luca Apruzzi, and Vincenzo Ardita, and Nicola Favia, and Concetta Saracino, and Niccolò Carta, and Germano Melissano, and Roberto Chiesa
June 2011, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists,
Copied contents to your clipboard!